QUARTI TREVANO, FOSCA ANNA LUISA
 Distribuzione geografica
Continente #
NA - Nord America 10.693
EU - Europa 5.482
AS - Asia 2.858
SA - Sud America 183
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 7
Totale 19.253
Nazione #
US - Stati Uniti d'America 10.534
SG - Singapore 1.281
DE - Germania 964
RU - Federazione Russa 918
IT - Italia 898
SE - Svezia 863
CN - Cina 701
IE - Irlanda 669
HK - Hong Kong 531
UA - Ucraina 424
GB - Regno Unito 242
BR - Brasile 155
CA - Canada 141
FI - Finlandia 126
AT - Austria 123
VN - Vietnam 75
IN - India 65
ID - Indonesia 64
FR - Francia 62
NL - Olanda 46
DK - Danimarca 41
TR - Turchia 31
BE - Belgio 24
CZ - Repubblica Ceca 23
JP - Giappone 22
IR - Iran 12
MX - Messico 10
KR - Corea 9
PH - Filippine 8
AU - Australia 7
IQ - Iraq 7
LK - Sri Lanka 7
MK - Macedonia 7
RO - Romania 7
UZ - Uzbekistan 7
BD - Bangladesh 6
EC - Ecuador 6
LT - Lituania 6
VE - Venezuela 6
CL - Cile 5
KE - Kenya 5
PE - Perù 5
PL - Polonia 5
AR - Argentina 4
ES - Italia 4
EU - Europa 4
HU - Ungheria 4
TW - Taiwan 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
MU - Mauritius 3
MY - Malesia 3
PK - Pakistan 3
PT - Portogallo 3
TN - Tunisia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AM - Armenia 2
BH - Bahrain 2
CH - Svizzera 2
EE - Estonia 2
GD - Grenada 2
GR - Grecia 2
HR - Croazia 2
IL - Israele 2
JO - Giordania 2
KG - Kirghizistan 2
MG - Madagascar 2
NG - Nigeria 2
NO - Norvegia 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
CR - Costa Rica 1
ET - Etiopia 1
GE - Georgia 1
JM - Giamaica 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
MN - Mongolia 1
PA - Panama 1
SA - Arabia Saudita 1
UG - Uganda 1
Totale 19.253
Città #
Ann Arbor 2.182
Fairfield 986
Woodbridge 936
Singapore 855
Houston 694
Frankfurt am Main 650
Dublin 633
Chandler 572
Hong Kong 529
Wilmington 505
Ashburn 502
Jacksonville 466
Seattle 360
Dearborn 317
Cambridge 307
New York 270
Milan 253
Princeton 246
Santa Clara 232
Lawrence 121
Altamura 120
Nanjing 113
Vienna 105
Shanghai 98
Beijing 95
Lachine 73
San Diego 67
Moscow 62
Boardman 54
Jakarta 51
Lissone 50
Dong Ket 44
Helsinki 43
Andover 42
Guangzhou 41
Nanchang 38
Council Bluffs 37
Hebei 31
London 26
Nuremberg 26
Toronto 26
Changsha 25
Fremont 25
Tianjin 25
Falls Church 24
Los Angeles 23
Rome 23
Ningbo 22
Shenyang 22
Brussels 21
Jiaxing 21
Brno 20
Jinan 20
Munich 20
Monza 19
Cinisello Balsamo 18
Kunming 18
Ottawa 18
Mountain View 16
Hangzhou 15
Norwalk 15
San Mateo 15
Huizen 14
São Paulo 14
Auburn Hills 13
Nürnberg 13
Sacramento 13
Zhengzhou 12
Hefei 11
Lappeenranta 9
Mumbai 9
Padova 9
Philadelphia 9
Düsseldorf 8
Monmouth Junction 8
Pune 8
Vimercate 8
Brasília 7
Edmonton 7
Groningen 7
Leawood 7
San Francisco 7
Busto Arsizio 6
Colombo 6
Detroit 6
Esslingen am Neckar 6
Fuzhou 6
Kiev 6
Malgesso 6
New Delhi 6
Redmond 6
Tashkent 6
Winnipeg 6
Akatsuka-shinmachi 5
Amsterdam 5
Belo Horizonte 5
Carate Brianza 5
Chicago 5
Dallas 5
Desio 5
Totale 13.577
Nome #
Heart rate as a sympathetic marker during acute adrenergic challenge 311
Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia 280
Sympathetic Neural Overdrive in the Obese and Overweight State: Meta-Analysis of Published Studies 255
Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction. 241
Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population 211
Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. 200
Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms 199
Sympathetic and baroreflex abnormalities in the uncomplicated prediabetic state 199
Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome 198
Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values 198
Sympathetic overdrive in the metabolic syndrome: meta-analysis of published studies 196
Sustained sympathoinhibitory effects of cardiac resynchronization therapy in severe heart failure 193
Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis 191
Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease 190
Iron Overload Increases Sympathetic Nervous Activity: Study in Hemochromatosis Patients at Diagnosis and Iron Depletion 190
Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study 189
Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study 188
Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan 185
Neurogenic abnormalities in masked hypertension 182
Multiple sampling improves norepinephrine reproducibility in essential hypertension: a comparison with the microneurographic technique 182
Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study 182
Sympathetic nerve traffic and baroreflex function in optimal, normal, and high-normal blood pressure states 181
Threshold and Target for Blood Pressure Lowering in the Elderly 180
Prevalence of cardiovascular risk factors in an unselected Italian population. Results of the CardioLab Project 2004-2008 179
Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity 178
Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: Results of a double-blind randomized multicentre trial 177
Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study 176
Incident Left Ventricular Hypertrophy in Masked Hypertension 175
Short- and long-term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension 173
Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives 172
Effects of hypertension and obesity on the sympathetic activation of heart failure patients 171
Iron overload exerts sympathoexcitatory effects in men with essential hypertension: microneurogtaphic evidence 171
Sympathetic Nerve Traffic and Arterial Baroreflex Function in Apparent Drug-Resistant Hypertension 170
Hypertension, antihypertensive treatment and stroke prevention 167
Cardiovascular risk and adrenergic overdrive in the metabolic syndrome 167
Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes 164
Autonomic Cardiovascular Alterations in Chronic Kidney Disease: Effects of Dialysis, Kidney Transplantation, and Renal Denervation 164
Neuroadrenergic activation in obstructive sleep apnoea syndrome: A new selectedmeta-analysis - revisited 164
Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events 163
Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials 163
Diurnal blood pressure variation and sympathetic activity 162
The PAMELA (Pressioni Arteriose Monitorate E Loro Associazioni) study: Main features and results 162
Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction 161
Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up 161
Response to possible difference in the sympathetic activation on extreme dippers with or without exaggerated morining surge 160
Baroreflex function in hypertension: consequences for antihypertensive therapy 158
Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis 158
Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications 157
Multicentre randomised, double blind, evaluation of nebivolol plus HCTZ and irbesartan plus HCTZ in the treatment of systolic hypertension in the elderly: the NEHIS Study 154
Should white-coat hypertension in diabetes be treated? Pro 150
HYT-Hypertension in Turkey: A Cross-Sectional Survey on Blood Pressure Control with Calcium Channel Blockers Alone or Combined with Other Antihypertensive Drugs 149
Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction 147
Reinforcement of the adrenergic overdrive in the metabolic syndrome complicated by obstructive sleep apnea 147
Pheochromocytoma as a Clinical Model of Peripheral Sympathetic Overdrive: Old and New Findings 146
Heart Rate, Sympathetic Cardiovascular Influences, and The Metabolic Syndrome 145
Blood pressure control and therapeutic modulation of the adrenergic overdrive 145
Clinical correlates and subclinical cardiac organ damage in different extreme dipping patterns 144
Blood pressure control in resistant hypertension: new therapeutic options 143
Early sympathetic activation in the initial clinical stages of chronic renal failure 142
Association between ADRA1A gene and the metabolic syndrome: candidate genes and functional counterpart in the PAMELA population 139
Sympathetic activation in congestive heart failure: an updated overview 139
Response to sympathetic activity, heart failure, obesity, and metabolic syndrome: Is there any role for obstructive sleep apnea? 138
Adrenergic and metabolic effects of bariatric surgey in obese subjects: a longitudinal study 138
Salt intake and sympathetic activity - Response 138
Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension 137
The 'neuroadrenergic hypothesis' in hypertension: current evidence 137
Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension 136
The "J curve" problem revisited: old and new findings 135
Left ventricular hypertrophy in isolated and dual masked hypertension 134
Sympathetic neural overdrive in congestive heart failure and its correlates: systematic reviews and meta-analysis 133
Left ventricular mass reduction and hypertrophy regression following renal artery revascularization: a meta-analysis 133
4C.07:Relationships between cognitive dysfunction, clinic and ambulatory blood pressure and blood pressure variability: results from the PAMELA Study 131
Early sympathetic activation in mild renal failure 131
Sympathetic activation in congestive heart failure: Reproducibility of neuroadrenergic markers 129
Sympathetic activation in congestive heart failure: Evidence, consequences and therapeutic implications 128
Blood pressure lowering effects of Rimonabant in obesità-related hypertension 127
Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives 127
Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project 127
The importance of pulse pressure on cardiovascular risk and total mortality in the general population: Is sex relevant? 126
Long-term changes in left ventricular mass echocardiographic findings from a general population 125
Blood pressure control and antihypertensive treatment 124
Behaviour of regional sympathetic nerve traffic in obstructive sleep apnea syndrome 121
Essential hypertension and the sympathetic nervous system 120
Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity 120
DIFFERING EFFECTS OF RENAL DENERVATION ON BLOOD PRESSURE AND SYMPATHETIC NERVE TRAFFIC: A SYSTEMATIC REVIEW AND META-ANALYSIS 119
Antihypertensive treatment and stroke prevention: From recent meta-analyses to the PRoFESS trial 119
Long-term risk of sustained hypertension in white-coat or masked hypertension 119
Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension 117
Limited reliability of heart rate as a sympathetic marker in chronic kidney disease 117
Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study 116
Muscle and skin sympathetic nerve traffic during physician and nurse blood pressure measurement 116
Left ventricular mass and incident out-of-office hypertension in a general population 115
Short- and Long-Term Reproducibility of Nighttime Blood Pressure Phenotypes and Nocturnal Blood Pressure Reduction 114
Uric acid and risk of new-onsetmetabolic syndrome, impaired fasting glucose and diabetesmellitus in a general Italian population: data from the Pressioni ArterioseMonitorate E Loro Associazioni study 113
Long QT interval and malignant ventricular arrhythmia during treatment with cisapride. Report of a clinical case 110
Adverse prognostic value of persistent office blood pressure elevation in White coat Hypertension 110
The PAMELA research project: a 25-year long journey 110
Sympathetic Neural Mechanisms Underlying Attended and Unattended Blood Pressure Measurement 107
Heart rate as a predictor of cardiovascular risk 106
Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome 102
Totale 15.589
Categoria #
all - tutte 81.821
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.821


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020388 0 0 0 0 0 0 0 0 0 159 167 62
2020/20212.492 155 147 209 259 175 221 220 239 186 293 140 248
2021/20222.063 165 171 263 201 177 162 110 83 110 128 195 298
2022/20232.814 320 813 274 271 165 453 48 157 159 20 89 45
2023/20242.231 56 56 112 120 298 501 387 74 252 67 51 257
2024/20253.971 321 721 250 268 518 185 299 278 607 524 0 0
Totale 19.863